{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:56:41Z","timestamp":1789394201788,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["499533307"],"award-info":[{"award-number":["499533307"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Iron deficiency anemia is treated by iron supplementation. Increasing evidence has shown that the carbohydrate components in iron infusions can cause hypophosphatemia and subsequent osteomalacia due to excess intact fibroblast growth factor 23 (iFGF23). We here undertook an in-depth characterization of 13 patients with iron infusion-induced osteomalacia (IIIO). Patients were characterized (monocentric institutional practice) by means of laboratory, bone density, HR-pQCT, and virtual osteoid volume estimation. We additionally report a patient who was treated with burosumab because iron infusions had to be continued despite osteomalacia. All 13 patients received ferric carboxymaltose (FCM) infusions and presented with low phosphate levels. Stopping the FCM infusions and supportive treatment by substitution of phosphate, calcium, native, and\/or active Vitamin D was the chosen therapeutic approach. Pain, mobility, and biochemical data, such as serum phosphate levels, BMD, bone microstructure, and virtual osteoid volume, were the main outcome measures. Our results indicate biochemical normalization (eg, phosphate levels pre: 0.50\u00a0mmol\/L\u2009\u00b1\u20090.23\u00a0mmol\/L, post: 0.93\u00a0mmol\/L\u2009\u00b1\u20090.32\u00a0mmol\/L, p&amp;lt;.001) after stopping the FCM infusion and establishing supportive treatment. Additionally, pain levels on the visual analog scale (VAS) decreased (VASpre 7.31\u2009\u00b1\u20091.22, VASpost 2.73\u2009\u00b1\u20091.27, p&amp;lt;.0001) and areal BMD (expressed by T-score) improved significantly (T-scorepre: \u22121.85\u2009\u00b1\u20091.84, T-scorepost: \u22120.91\u2009\u00b1\u20092.13, p&amp;lt;.05). One patient requiring ongoing FCM infusions experienced significant additional benefits from burosumab treatment. In conclusion, our results highlight the importance of monitoring phosphate in patients treated with FCM infusions. Stopping FCM infusions is effective in addressing the excess of iFGF23 and thereby phosphate wasting. Supportive therapy enables quick recovery of the musculoskeletal system and improves pain levels in these patients.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziae139","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T11:31:03Z","timestamp":1731151863000},"source":"Crossref","is-referenced-by-count":6,"title":["In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6586-6794","authenticated-orcid":false,"given":"Felix N","family":"von Brackel","sequence":"first","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Lottestrasse 59, 22529 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Grambeck","sequence":"additional","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Lottestrasse 59, 22529 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Barvencik","sequence":"additional","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Lottestrasse 59, 22529 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Amling","sequence":"additional","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Lottestrasse 59, 22529 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-5013","authenticated-orcid":false,"given":"Ralf","family":"Oheim","sequence":"additional","affiliation":[{"name":"Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf , Lottestrasse 59, 22529 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"10270","key":"2025022412474165500_ref1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","article-title":"Iron deficiency","volume":"397","author":"Pasricha","year":"2021","journal-title":"Lancet"},{"key":"2025022412474165500_ref2","volume-title":"Global Nutrition Targets 2025: Anaemia Policy Brief"},{"issue":"1","key":"2025022412474165500_ref3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2025022412474165500_ref4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025022412474165500_ref5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"2025022412474165500_ref6","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"2025022412474165500_ref7","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a complication of intravenous iron infusion: a systematic review of case reports","volume":"37","author":"Vilaca","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025022412474165500_ref8","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","article-title":"Intravenous iron-induced hypophosphatemia: an emerging syndrome","volume":"38","author":"Glaspy","year":"2021","journal-title":"Adv Ther"},{"key":"2025022412474165500_ref10","doi-asserted-by":"publisher","first-page":"bcr-2017-222851","DOI":"10.1136\/bcr-2017-222851","article-title":"Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration","volume":"2018","author":"Klein","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2025022412474165500_ref11","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"issue":"4","key":"2025022412474165500_ref12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"issue":"9","key":"2025022412474165500_ref13","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00198-020-05438-5","article-title":"Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography","volume":"31","author":"Whittier","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025022412474165500_ref14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00223-023-01143-7","article-title":"Comparison of motion grading in 1,000 patients by first- and second-generation HR-pQCT: a propensity score matched cohort study","volume":"113","author":"Bartosik","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2025022412474165500_ref15","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/jbmr.3128","article-title":"The estimation of second-generation HR-pQCT from first-generation HR-pQCT using in vivo cross-calibration","volume":"32","author":"Manske","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025022412474165500_ref16","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/jbmr.2873","article-title":"Sex- and site-specific normative data curves for HR-pQCT","volume":"31","author":"Burt","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025022412474165500_ref17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00223-013-9808-5","article-title":"Bone microarchitecture and estimated strength in 499 adult Danish women and men: a cross-sectional, population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure","volume":"94","author":"Hansen","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2025022412474165500_ref18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1093\/jbmr\/zjae008","article-title":"Approaching virtual osteoid volume estimation and in-depth tissue characterization in patients with tumor-induced Osteomalacia","volume":"39","author":"Schmidt","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025022412474165500_ref9","doi-asserted-by":"publisher","first-page":"ziae064","DOI":"10.1093\/jbmrpl\/ziae064","article-title":"Iron and bones: effects of iron overload, deficiency and anemia treatments on bone","volume":"8","author":"von Brackel","year":"2024","journal-title":"JBMR Plus"},{"issue":"12","key":"2025022412474165500_ref19","doi-asserted-by":"publisher","first-page":"1900287","DOI":"10.1002\/advs.201900287","article-title":"On the origins of fracture toughness in advanced Teleosts: how the swordfish Sword\u2019s bone structure and composition allow for slashing under water to kill or stun prey","volume":"6","author":"Schmidt","year":"2019","journal-title":"Adv Sci"},{"issue":"1893","key":"2025022412474165500_ref20","doi-asserted-by":"publisher","first-page":"20181820","DOI":"10.1098\/rspb.2018.1820","article-title":"Ultra-high matrix mineralization of sperm whale auditory ossicles facilitates high sound pressure and high-frequency underwater hearing","volume":"285","author":"Schmidt","year":"2018","journal-title":"Proc Biol Sci"},{"issue":"9","key":"2025022412474165500_ref21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jbmr.4641","article-title":"Bone matrix mineralization and response to burosumab in adult patients with X-linked hypophosphatemia: results from the phase 3, single-arm international trial","volume":"37","author":"Fratzl-Zelman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025022412474165500_ref22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025022412474165500_ref23","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/rheumatology\/kez627","article-title":"Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia","volume":"59","author":"Amarnani","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziae139\/60575549\/ziae139.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae139\/60988794\/ziae139.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/1\/ziae139\/60988794\/ziae139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:48:10Z","timestamp":1740401290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziae139\/7888802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziae139","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,11,9]]},"article-number":"ziae139"}}